title: Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
abstract: In its third edition, the Stem Cell and Regenerative Medicine Global Conference (SCRGC) organized by the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) was focused on breaking barriers to accelerate the pace of innovation and development of the regenerative medicine industry. GSRAC is both a think tank and a global network of key opinion leaders from the public and the private sectors. GSRAC was commissioned in 2011 by the Ministry of Health and Welfare (MOHW) of Korea. GSRAC's primary mission is to enable and accelerate the delivery of innovative technologies to patients who are affected by currently untreatable diseases. This goal is notably achieved by resolving hurdles in the field of regenerative medicine. With a total of 30 speakers and panelists from 8 different countries and more than 400 attendees from an array of institutions including hospitals, clinics, biotechnology companies, pharmaceutical companies, scientists, as well as policy makers, the 2-day SCRGC highlighted critical challenges and paths to resolving them in policy and regulatory, and industrial-scale manufacturing of gene-based and cell-based therapies, comprising plenary lectures and sessions covering strategic policy, regulatory, reimbursement and business development, and business of manufacturing, and production technologies. Several of these presentations are summarized in this report.
authors.affiliation: NxR Biotechnologies, Basel, Switzerland. info@nxrbiotech.com.
authors.forename: A
authors.initials: A
authors.lastname: Vertès
mesh_terms: D001709:Biotechnology; D006291:Health Policy; D006801:Humans; D062069:Inventions; D011057:Politics; D055818:Public-Private Sector Partnerships; D044968:Regenerative Medicine / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods*; D012051:Reimbursement Mechanisms; D056910:Republic of Korea; D013234:Stem Cells
keywords: Accelerated regulatory approval pathways; Cell therapies manufacturing; Cell-based therapies; Gene-based therapies; Global Haplobank initiative; Pricing and reimbursement of curative therapeutics; Regenerative medicine